New drug combo aims to shrink plasma cell tumors

NCT ID NCT04174196

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs (lenalidomide and CC-486) with radiation therapy is safe and works well for people with plasmacytoma, a tumor made of plasma cells. About 21 adults with newly diagnosed or returning plasmacytoma will take part. The main goal is to see if the tumor disappears completely after 6 treatment cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasmacytoma primary plasmacytoma of the bone solitary osseous plasmacytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA PLASMACYTOMA PLASMACYTOMA OF BONE

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.